NCT07649564

Brief Summary

To investigate the clinical effects of probiotics in relieving chronic constipation in adults, and evaluate the improvement of symptoms in patients with constipation as well as their impacts on gastrointestinal function and gut microbiota.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 2, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 9, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 4, 2024

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

June 10, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 16, 2026

Completed
Last Updated

June 16, 2026

Status Verified

June 1, 2026

Enrollment Period

1 month

First QC Date

June 10, 2026

Last Update Submit

June 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • 1. Assessing the Improvement of Chronic Constipation Symptoms Following Probiotic Intervention.

    Constipation symptoms are measured using Bristol Stool Form Scale, which classifies stool into seven types (1-2 indicate constipation, 3-4 normal, and 5-7 diarrhea) for self-assessment or clinical evaluation of bowel function.

    8 weeks

Study Arms (2)

Probiotic Group

EXPERIMENTAL

Participants receive one sachet per day containing probiotic BC99 and maltodextrin (Week 0 to Week8).

Dietary Supplement: Probiotic

Placebo Group

PLACEBO COMPARATOR

Participants receive one sachet per day containing maltodextrin only, serving as the placebo(Week 0 to Week8).

Dietary Supplement: Placebo

Interventions

ProbioticDIETARY_SUPPLEMENT

During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.

Probiotic Group
PlaceboDIETARY_SUPPLEMENT

During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.

Placebo Group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) Chinese adults aged 18-70 years who meet the Rome IV diagnostic criteria for chronic constipation (duration of at least 6 months, with less than three passing stools per week and/or Bristol Stool Scale types 1 and 2); (2) The patient rarely experiences diarrhea without using laxatives; (3) The criteria for irritable bowel syndrome were insufffcient ; (4) patients that could complete the study according to the requirements of the trial protocol; (5) participants (including male subjects) who have no family planning within 14 days prior to screening and voluntarily take effective contraceptive measures within 6 months after the end of the trial; (6) Patients capable of understanding the clinical study and willing to comply with the study requirements and procedures; (7) Subjects who have signed the informed consent form. Only those who meet all the above conditions can be selected for the study.

You may not qualify if:

  • Use of probiotics, prebiotics, or antibiotics within two weeks prior to enrollment and throughout the intervention period;
  • Regular use of a high-fiber diet, as measured by the recommended food score (RFS);
  • Regular use of medications affecting bowel habits, such as irritable bowel syndrome, functional bloating, and functional diarrhea;
  • Currently have, or have had in the past 2 years, any gastrointestinal conditions such as: Crohn's disease, celiac disease, ulcerative colitis, malignant tumor of the colon;
  • Medical history of cardiovascular, liver, or renal diseases; alcoholics;
  • Hypersensitivity to probiotics or the ingredients used in this study;
  • Pregnancy or breastfeeding;
  • Participation in another clinical trial in the 3 months before enrollment. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The School of Food and Bioengineering, Henan University of Science and Technolog

Luoyang, Henan, 471000, China

Location

MeSH Terms

Interventions

Probiotics

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2026

First Posted

June 16, 2026

Study Start

July 2, 2024

Primary Completion

August 9, 2024

Study Completion

October 4, 2024

Last Updated

June 16, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations